Press releases
- MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)
- MindMed to be Included in Russell 2000® and Russell 3000® Indexes
- MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
- MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
- MindMed to Participate in June Conferences
- MindMed to Participate at May Investor Conferences
- New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US
- MindMed Reports First Quarter 2024 Financial Results and Business Updates
- MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
- MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update
More ▼
Key statistics
On Monday, Mind Medicine (MindMed) Inc (MMQ:MUN) closed at 7.20, -40.49% below its 52-week high of 12.09, set on Apr 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.20 |
---|---|
High | 7.20 |
Low | 7.20 |
Bid | -- |
Offer | -- |
Previous close | 7.20 |
Average volume | 545.40 |
---|---|
Shares outstanding | 71.87m |
Free float | 71.02m |
P/E (TTM) | -- |
Market cap | 603.01m USD |
EPS (TTM) | -2.94 USD |
Data delayed at least 15 minutes, as of Jul 22 2024 07:00 BST.
More ▼